Awaiting a new era of cancer immunotherapy

Cancer Research

Volumn 72, Issue 15, 2012, Pages 3715-3719

  Hong, Cheng William ^a   Zeng, Qi ^b,c  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CELL PROTEIN; MT PROTEIN; ONCOPROTEIN; PHOSPHATASE; PROTEIN EGFP; PROTEIN PRL3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; BINDING AFFINITY; CANCER IMMUNOTHERAPY; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW;

ANIMALS; ANTIGENS; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84864862869     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0063     Document Type: Review

References (28)

1. Ledford H. 'Biosimilar' drugs poised to penetrate market. Nature 2010;468:18-9.
2. Baker M. Upping the ante on antibodies. Nat Biotechnol 2005;23: 1065-72.
3. Cohen J, Wilson A. New challenges to Medicare beneficiary access to mAbs. MAbs 2009;1:56-66.
4. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
5. Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 2011;3:99ra85.
6. Zeng Q, Hong W, Tan YH. Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun 1998;244:421-7.
7. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001;294:1343-6.
8. Bessette DC, Qiu D, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 2008;27:231-52.
9. Al-Aidaroos AQO, Zeng Q. PRL-3 phosphatase and cancer metastasis. J Cell Biochem 2010;111:1087-98.
10. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
11. Dilworth SM. Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer 2002;2:951-6.
12. Ruiz-Argüelles A, Alarcón-Segovia D. Penetration of autoantibodies into living cells, 2000. Isr Med Assoc J 2001;3:121-6.
13. Alarcon-Segovia D, Ruiz-Arguelles A, Fishbein E. Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature 1978;271:67-9.
14. Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH, Liu WT. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology (Oxford) 2001;40:750-6.
15. Tezel G, Wax MB. The mechanisms of hsp27 antibody-mediated apoptosis in retinal neuronal cells. J Neurosci 2000;20:3552-62.
16. Golan TD, Gharavi AE, Elkon KB. Penetration of autoantibodies into living epithelial cells. J Invest Dermatol 1993;100:316-22.
17. Vlahakos D, Foster MH, Ucci AA, Barrett KJ, Datta SK, Madaio MP. Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol 1992;2:1345-54.
18. Sager JA, Benvenuti S, Bardelli A. PRL-3: a phosphatase for metastasis? Cancer Biol Ther 2004;3:952-3.
19. Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, et al. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell 2010;18:52-62.
20. Guo K, Tang JP, Jie L, Al-Aidaroos AQ, Hong CW, Tan CP, et al. First chimeric antibody in targeting intracellular oncoprotein for cancer therapy in Mice. Oncotarget 2012;3:158-71.
21. Singhal A, Hakomori S. Molecular changes in carbohydrate antigens associated with cancer. Bioessays 1990;12:223-30.
22. Guo K, Tang JP, Tan CPB, Wang H, Zeng Q. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther 2008;7:750-7.
23. Cooper S. Reappraisal of serum starvation, the restriction point, G0, and G1 phase arrest points. FASEB J 2003;17:333-40.
24. Nickel W, Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 2009;10:148-55.
25. Ferrone S. Hidden immunotherapy targets challenge dogma. Sci Transl Med 2011;3:99ps38.
26. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68.
27. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010;29:4989-5005.
28. Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev 2010;24:171-82.